Sarepta gene therapy for Duchenne muscular dystrophy fails on function — raising serious questions about all their drugs
Sarepta $SRPT has some explaining to do.
After the market closed on Thursday the controversial biotech company reported that their next-gen gene therapy approach to Duchenne muscular dystrophy did what it was supposed to do in spurring a significant increase in dystrophin production, but failed on the key endpoint that aimed to demonstrate improved muscle function for the boys afflicted with this lethal condition.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.